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T he number of patients treated with total hip arthroplasty (THA) has increased year by year.  
THA provides pain relief and improves the activities of 
daily living and the quality of life of affected patients.  
However,  deep prosthetic infection is a serious compli-
cation following THA,  and is reported to occur in 
about 0.3 to 3% of primary THA,  and 4 to 6% of revi-
sion procedures [1 , 2].  Although several strategies have 
been described for managing deep prosthetic infection 
following THA [3-6],  to date there is no consensus on 
the best strategy.  Two-stage revision is the most com-
monly used treatment for deep prosthetic infection,  
with reported infection eradication rates of 90% or 
higher [7-9].  It is the recommended technique for anti-
biotic-resistant organisms such as methicillin- 
resistant Staphylococcus aureus (MRSA),  gram-negative 
bacilli,  and fungi,  and for patients with immunodefi-
ciency (e.g.,  diabetes mellitus (DM),  malignant tumors,  
use of steroids) or widespread chronic infected fistulae 
[3 , 5 , 7 , 10-13].  However,  two-stage THA revision is 
poorly tolerated by patients,  owing to the restriction of 
weight-bearing and mobility during the interval 
between the first and second stages.  Patients are known 
to be severely distressed during this interval,  both phys-
ically and mentally [15].
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Two-stage revision total hip arthroplasty (THA) is the most commonly used treatment approach for deep pros-
thetic infection.  However,  in this approach the interval between the first and second stage tends to be pro-
longed.  We devised a strategic protocol for improving the infection eradication rate and shortening the interval 
between the stages in two-stage revision THA.  This study analyzed a series of 14 patients (14 hips) from 2008 to 
2012,  who were treated using an antibiotic-loaded acrylic cement (ALAC) spacer at the first stage and re-im-
plantation at the second stage.  The ALAC included vancomycin and amikacin for most of the cases.  Patients 
with MRSA infection were additionally administered intravenous vancomycin in combination with either oral 
rifampicin or trimethoprim-sulfamethoxazole.  The average interval between the stages was 54.2 days overall,  
and 58.7 days for cases with MRSA infection.  Our infection eradication rate was 100%,  with no reported 
recurrence of infection.  The presence of MRSA tended to be associated with a longer interval between the two 
stages.  Our protocol for two-stage revision THA was associated with a high eradication rate of infection and a 
shortened interval between the stages.
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The recent introduction of antibiotic-loaded acrylic 
cement (ALAC) as an effective local delivery system of 
antibiotics has contributed to effective control of deep 
prosthetic infection [7 , 8 , 15].  The antibiotic concen-
tration in resected joint spaces following the use of 
ALAC exceeds systemic levels [15].
Cement-less femoral fixation is generally used for 
second-stage re-implantation,  and is reported to have 
good results [13 , 16 , 17].  One benefit of this choice is 
avoiding the difficulty of removing the implant and 
cement in the event of recurrence of infection.  This is 
especially relevant in cases wherein removal of the fem-
oral stem may result in femoral fracture and bone stock 
loss.  However,  the interval between the stages in 
cement-less revision tends to be longer because sur-
geons must wait until the markers of infection are com-
pletely negative.
Several studies have reported good eradication rates 
of infection with one-stage ALAC fixation in selected 
patients [6 , 18 , 19].  Although the treatment duration of 
one-stage revision is shorter than that of the other avail-
able treatments [20],  its application is limited.  In the 
event of infection recurrence in these cases,  the course 
of treatment becomes difficult.  In view of these con-
cerns,  we have been treating infected THAs with a 
short-term ALAC spacer followed by ALAC implant 
fixation as a part of the two-stage revision of THAs 
since 2008.  This method has the advantage of a pro-
longed period of local antibiotics at a high concentra-
tion owing to the use of ALAC both as a spacer and for 
implant fixation.  In this study,  we examined the suc-
cess rate of two-stage revision using ALAC in these dual 
roles.  In addition,  we analyzed the factors that contrib-
uted to prolongation of the interval between the first 
and second stage of THA revision.
Materials and Methods
The medical records of 14 patients treated for 
infected THA between April 2008 and September 2012 
were reviewed in this retrospective study.  All patients 
underwent two-stage revision THA on 1 hip each per 
our protocol.  There were 8 men and 6 women with a 
mean age of 69.4 years (SD,  11.6 years; range,  58-83 
years).  The average body mass index was 22.5 ± 3.3 kg/
m2.  The average follow-up period was 4.9 ± 1.5 years.  
The diagnosis of infection in all patients was based on 
clinical history,  physical examination (e.g.,  fever,  pain 
on movement,  night pain,  flare,  swelling),  diagnostic 
imaging (plain radiographs,  magnetic resonance imag-
ing,  and three-layer bone scintigraphy with Tc99m),  
laboratory evaluation (leukocyte cell total and differen-
tial count,  C-reactive protein [CRP],  erythrocyte sedi-
mentation rate,  and aspirated hip synovial fluid analysis 
(differential white blood cell count,  glucose concentra-
tion,  and bacterial culture) [3 , 5 , 7 , 21].  The diagnosis 
of infection was based on a comprehensive assessment 
of these parameters in the absence of clear bacterial 
identification.  After establishing the diagnosis of infec-
tion,  patients were managed according to our strategic 
protocol for shortening the treatment duration of the 
two-stage revision (Fig. 1).  Our protocol mainly con-
sisted of customized antibiotics in ALAC,  addition of 
intravenous and oral antibiotics for MRSA,  timing of 
cultures after antibiotics,  and specific criteria for deter-
mining the time required to perform re-implantation.  
In the first stage,  we removed the implant and set an 
ALAC spacer after thorough debridement of the 
implant site.  The relevant antibiotic powder was added 
at a ratio of 5 g to 40 g of cement spacer.  Vancomycin 
(Shionogi,  Osaka,  Japan) and amikacin (Nichiiko,  
Toyama,  Japan) were used for most patients,  and also 
in the absence of sensitivity data.  One patient received 
teicoplanin (TARGOCID®; Sanofi,  Paris,  France) in 
ALAC as he was allergic to vancomycin.  We used a 
2-mm k-wire (Mizhuho,  Tokyo,  Japan) as the core for 
the cement rod in the femoral bone marrow cavity,  and 
beads in the acetabular space.  All patients with non-
MRSA infection received intravenous first-generation 
cefazolin sodium (NIPRO,  Osaka,  Japan) at 4 g/day for 
three days,  to prevent surgical site infections following 
the first-stage procedure.  Patients with MRSA infection 
received vancomycin injection through a central venous 
access.  In addition,  these patients received a rifampicin 
capsule (Sandoz,  Tokyo,  Japan) at 450 mg/12 h or tri-
methoprim-sulfamethoxazole (TMP-SMX) (Bactor®;  
Shionogi,  Osaka,  Japan) at 1 tablet/8 h through the oral 
route.  The maximum duration of antibiotic therapy was 
4 weeks for MRSA.  During treatment,  patients were 
monitored for side effects by laboratory evaluations 
repeated once or twice a week.  The antibiotic regimen 
was shortened to less than 4 weeks if the infection 
marker showed improvement (CRP < 1.0 mg/dL) in the 
postoperative period.  Two weeks following the cessa-
tion of antibiotic therapy,  the synovial fluid was cul-
tured for bacteria and analyzed for differential white 
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blood cell count and glucose concentration.  A 2-week 
interval was used to account for any residual effect of 
the antibiotics.  Our criteria for presuming an absence of 
infection were a CRP value < 3 mg/dL in addition to 
synovial fluid demonstrating the following: absence of 
bacterial isolates; neutrophil rate < 50%; and neutro-
phil count < 2,000 cells/mL.  At the second stage,  the 
final decision for re-implantation was taken intra-oper-
atively,  provided that there were no signs of persistent 
infection and that the intra-operative frozen section 
demonstrated less than 10 polymorphic neutrophils 
(PMN; at 400 × magnification).  In the presence of 
more than 10 PMN,  re-implantation was deferred and 
the cement spacer was replaced.  The ALAC used 
during revision surgery consisted of only 1-2 g of anti-
biotic powder for 40 g of cement to avoid weakening the 
cement.  If the acetabular bone defect was large,  we 
used a Kerboull-type acetabular reinforcement device 
(K-MAX KT plate S®; Kyocera Medical,  Kyoto,  Japan).
The following study parameters were analyzed to 
assess their role in prolonging the waiting period 
between the first- and second-stage procedures: 1) 
presence of fistula; 2) comorbidity; 3) classification of 
infection (referring to Tsukayama’s report [22],  we 
defined the following types: type 1,  positive intraoper-
ative cultures; type 2,  early postoperative infection ( < 4 
weeks); type 3,  acute hematogenous infection; and 
type 4,  late chronic infection ( > 4 weeks)); and 4) 
presence of MRSA.
Statistical analyses. All numerical data are 
expressed as the means ± standard deviations.  The 
unpaired T test (Welch’s t test) or Fisher’s exact test were 
used to identify statistically significant differences 
between continuous variables or discrete variables,  
respectively.  All analyses were performed using statisti-
cal software JMP pro 12 (SAS Institute,  Cary,  NC,  
USA).  P values < 0.05 were considered statistically sig-
nificant.
Ethics statement. This study met the guidelines of 
the responsible government agency and complied with 
the principles of the Declaration of Helsinki.  The study 
design was approved by the Ethics Committee at 
Wakayama Medical University.  The patients or their 
families were informed that the data from the cases 
would be submitted for publication,  and their consent 
was obtained.
Results
All 14 patients managed according to our protocol 
eventually recovered from prosthetic infection.  The 
overall average ALAC spacer period between the first- 
and the second-stage was 54.2 ± 17.1 days.  A single use 
of ALAC spacer was adequate in 11 patients (mean 
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Diagnosis of THA infection 
MRSA MSSA Unclear
1st-stage ALAC spacer (VCM+AMK total 5g/40g cement)
+ VCM i.v
+Rif or TMP-SMX p.o
+ Cefazolin i.v (3 days)
2nd-stage
ALAC ﬁxation (VCM+AMK total 1-2g/40g cement)
(for 4 weeks*)
at 4 weeksat 6 weeks
Synovial ﬂuid culture
neutrophil rate <50%, neutrophil count <2000
in joint puncture ﬂuid and CRP <3
intra-operative frozen section <10 polymorphic neutrophils
Negative
Positive
Yes
No
Yes
No
＊This additional treatment stopped if CRP showed below 1.0 during postoperative course.
Fig. 1　 Treatment protocol for two-
stage revision THA in our hospital.  
ALAC,  antibiotic-loaded acrylic cement;  
MRSA,  methicillin-resistant Ｓｔａpʰｙˡｏ︲
ｃｏｃｃｕｓ aureus; MSSA,  methicillin-sen-
sitive Staphylococcus aureus; VCM,  
vancomycin ; AMK,  amikacin ; Rif,  
r i fampicin ; TMP -SMX,  tr imetho -
prim-sulfamethoxazole.
waiting period,  48.3±10.1 days).  Three patients required 
a second use of ALAC (40.0 ± 15.1 days before ALAC 
replacement; 75.7 ± 22.8 days of total ALAC spacer 
period).  There was no recurrence of infection at the 
final follow-up in any of the cases.  Thus,  our infection 
eradication rate was 100%,  which represents a good 
result.
Bacterial cultures isolated MSSA in 3 patients and 
MRSA in 4 patients.  Bacterial cultures were inconclu-
sive in 6 patients.  Comorbidity related to underlying 
medical conditions such as rheumatoid arthritis,  DM,  
cardiac failure and intractable foot ulcer secondary to 
congenital insensitivity to pain were seen in 10 patients.  
Four patients had fistulae.  On classifying the infection,  
4 patients were of type 4 (Table 1).  Almost all patients 
received vancomycin and amikacin as the antibiotic 
components of ALAC,  except one patient who was 
allergic to vancomycin.
In these case series,  there was none of the included 
cases; a value of CRP > 3 mg/dL (the average value in all 
cases was 0.68±0.27 mg/dL); neutrophil rate >50%,  and 
neutrophil count > 2,000 cells/mL (the average value in 
all cases was 2,272 ± 729 cells/mL) before undergoing 
the second-stage procedure.  The average CRP value just 
before the second-stage procedure was 0.62 ± 1.02 mg/
dL for patients managed by a single setting of ALAC 
spacer (group A),  and 0.43 ± 0.18 mg/dL for patients 
requiring ALAC spacer replacement (three-stage proce-
dure) (group B).  The difference between the CRP values 
of the two groups was not significant (Table 2a).
The presence of MRSA infection was associated with 
prolonged interval between the first- and the sec-
ond-stage procedures.  The interval between the stages 
was significantly longer in the MRSA group compared 
to the non-MRSA group (62.0 ± 5.4 days vs. 51.1 ± 19.4 
days,  p = 0.0335) The presence of fistulae,  comorbidity,  
and classification of infection (type 1-3 vs. 4) was not 
found to be associated with prolonged interval between 
the stages (Table 2b).  Moreover,  the Fisher’s exact test 
showed no significant difference in risk factors between 
groups A and B (Table 2c).  Group B has a higher trend 
of the presence of MRSA than group A,  although the 
difference was not significant (p = 0.1768)
Discussion
The use of our protocol was associated with an aver-
age interval of 54.2 ± 17.1 days between the two stages of 
revision THA in our series.  In patients with MRSA 
infection,  this duration was significantly longer (aver-
age period,  58.7 days).  The intervals recorded in the 
present series were shorter than the waiting periods 
reported in systematic reviews or meta-analysis reports 
[8 , 9 , 16 , 23 , 24].  In addition,  our final infection eradi-
cation rate was 100% with no reported infection recur-
rence.  These results are indicative of a favorable out-
come with the adoption of our protocol,  and likely 
contributed to patient satisfaction.
We used vancomycin and amikacin as components 
of ALAC in most of the cases we managed.  This is 
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Table 1　 Patient characteristics
Patient Age sex
Identiﬁed 
bacteria
Antibiotics in 
ALAC
Total days between 
stages
Times of ALAC Infection type Fistula Comorbility
1 63y M MSSA VCM, AMK 45 1 4 －
2 70y M MRSA VCM, AMK 63 2 3 －
3 63y M MRSA VCM, AMK 55 1 3 ＋ RA, Nephrosis
4 83y F MSSA VCM, AMK 42 1 3 ＋ Cardiac insuﬃciency
5 71y F unclear VCM, AMK 45 1 4 － DM
6 58y M unclear VCM, AMK 35 1 4 － RA, Myasthenia gravis
7 73y M MSSA VCM, AMK 102 2 1 － Coronary aneurysm
8 76y F MSSA VCM, AMK 33 1 3 －
9 80y M unclear VCM, AMK 57 1 3 ＋ Cardiac insuﬃciency
10 72y M MSSA VCM, AMK 49 1 3 －
11 38y M MSSA TEIC, AMK 49 1 2 － Congenital insensitivity to pain
12 82y F unclear VCM, AMK 54 1 3 － Mammakrebs
13 74y F MRSA VCM, AMK 62 2 2 ＋ DM
14 68y F MRSA VCM, AMK 68 1 4 － DM, Hepatic cirrhosis
MSSA,  Methicillin-sensitive Staphylococcus aureus; MRSA,  Methicillin-resistant Staphylococcus aureus; VCM,  vancomycin; AMK,  ami-
kacin; ALAC,  antibiotic-loaded acrylic cement;  RA,  rheumatoid arthritis; DM,  diabetes mellitus.
because aminoglycosides are known to have a synergis-
tic effect on the bactericidal activity of vancomycin [25].  
The duration of antibiotic therapy remains controver-
sial.  Most centers prescribe intravenous antibiotic ther-
apy for 6 weeks followed by a further course of oral 
antibiotics.  Re-implantation is usually conducted at 6 to 
12 weeks in many centers [8 , 24].  Vielgut reported that 
their average waiting period between the two stages was 
12.6 weeks [26].  In their study,  the eradication rates of 
cases having 4- to 11-week intervals were better than 
those under 4 weeks,  or over 11 weeks.  Although our 
most important goal was the eradication of infection,  
the duration of intravenous antibiotic therapy was lim-
ited to 4 weeks to reduce the interval between the two 
stages.  According to our protocol,  the main approach 
to the treatment of infection was the use of ALAC,  with 
intravenous antibiotic therapy playing a secondary role.  
It has been reported that the inhibitory concentration of 
ALAC is maintained for 4-6 weeks with the antibiotic 
combination of vancomycin and aminoglycosides 
[15 , 27].  However,  Chang reported sustained 3 to 4 
weeks’ delivery of vancomycin from ALAC,  above the 
minimum inhibitory concentration,  when 4 g of anti-
biotic powder was used per 40 g of cement [28].  
Stockley reported that ALAC alone was adequate for 
treatment of implant site infections,  without the need 
for additional oral or intravenous antibiotics [29].  
Therefore,  we considered the continuation of intrave-
nous antibiotic therapy beyond 4 weeks as unnecessary.
Our analysis demonstrated that the presence of 
MRSA infection could be a factor associated with a pro-
longed interval between the first and second stage.  
Neither the presence of fistulae or comorbidity,  nor 
infection classification was a risk factor for a prolonged 
interval in our analysis.  Our protocol included addi-
tional treatment using intravenous vancomycin with 
oral administration of rifampicin or TMP-SMX for 
patients with MRSA infection.  The choice of additional 
antibiotic therapy was based on pharmacokinetics/
pharmacodynamics theory [30].  It has been reported 
that the addition of rifampicin is effective in breaching 
the bio-film of Staphylococcus aureus often associated 
with deep prosthetic infection [3 , 31 , 32].  Similarly,  the 
combination of TMP-SMX is known to be effective 
against MRSA [3 , 33 , 34].  Although it is difficult to 
control MRSA infection following THA,  and the pub-
lished eradication rates are lower than in non-MRSA 
infections [23 , 35],  our final eradication rate was 100%.
In our study,  there was no significant difference in 
CRP levels before re-implantation between the two-
stage revision and the three-stage revision groups.  
Hoell reported that serum CRP levels (cut-off-value:  
2.3 mg/dL) before re-implantation had a sensitivity of 
42.1% and specificity of 84.2% for persistent infection.  
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Table 2　 Factors contributing to prolonged interval between the 2 stages
a
Two-stage group Three-stage group p value
CRP 0.62±1.02 0.43±0.18 p＝0.2475
b
total periods betwwen stages p value
non-MRSA/MRSA 51.1±9.4 62.0±5.4 p＝0.0335
ﬁstula －/＋ 54.3±20.0 54.0±8.5 p＝0.6707
infection type 1-3/4 56.6±18.3 48.3±14.0 p＝0.3951
comorbility －/＋ 47.5±8.6 56.9±5.4 p＝0.8128
c
Two-stage group Three-stage group p value
non-MRSA/MRSA 9/2 1/2 p＝0.1758
ﬁstula －/＋ 8/3 2/1 p＝0.6703
infection type 1-3/4 7/4 3/0 p＝1.0000
comorbility －/＋ 3/8 1/2 p＝0.8242
Moreover,  he reported a sensitivity and specificity of 
5% and 99% for synovial fluid cultures,  and 31.3% and 
39.1% for synovial fluid leukocyte count (cut-off-
value: 970) before re-implantation [36].  The sensitivity 
data of all these markers are very low,  and although 
they contributed to the decision to perform a re-im-
plantation in our series,  the final decision was made 
only intra-operatively.  We relied on an intra-operative 
frozen section demonstrating less than 10 PMN (at ×400 
magnification).  This approach has a sensitivity and 
specificity of 84% and 99%,  respectively [37],  and 
appears to be a reliable indicator for decisions regarding 
re-implantation.  Hoell reported that the sensitivity and 
specificity for synovial fluid leukocyte count before 
re-implantation was low [36],  while Trampuz reported 
that a synovial fluid leukocyte differential of > 65% neu-
trophils or a leukocyte count of > 1,700 cells/mL is a 
sensitive (97%) and specific (98%) test for the diagnosis 
of prosthetic infection [38].  Another report showed that 
a synovial fluid leukocyte count of < 2,000 cells/mL and 
a differential with < 50% polymorphonuclear leukocyte 
cells had a 98% negative predictive value for the absence 
of prosthetic infection [39].  In a recent study,  a leuko-
cyte count of 4,200 cells/mL had a sensitivity of 84% 
and a specificity of 93% at detecting prosthetic hip 
infection [40].  Based on these pieces of evidence,  one 
of our criteria for deciding the absence of infection was 
a neutrophil rate < 50% and a neutrophil count < 2,000  
cells/mL in the synovial fluid.
Recent reports have demonstrated good clinical 
results with one-stage revision THA [6 ,18,19].  However,  
the choice of a one-stage revision requires careful 
judgement because it is difficult to remove the implant 
and the cement in the event of recurrence of infection.  
Two-stage revision is the gold standard for revision 
THA.  However,  two-stage revision contributes to 
physical and mental distress for patients owing to the 
prolonged interval between the stages [14].  Our proto-
col may clarify the principles of treatment in these 
cases.  Our results showed a high infection eradication 
rate and a shortened interval between the stages in two-
stage revision THA.  Therefore,  we propose our proto-
col as a reliable approach in the management of deep 
prosthetic infection following THA.
There are certain limitations of our study.  First,  the 
sample size was small and our results need to be vali-
dated by a larger study.  Second,  we did not perform 
multivariate analysis to identify factors contributing to 
a prolonged interval.  Third,  this was only a retrospec-
tive study.
In conclusion,  we devised a strategic protocol for 
improving the infection eradication rate and shortening 
the interval between the stages of two-stage revision 
THA.  Among patients managed by this protocol,  the 
average interval between stages was 54.2 days overall,  
and 58.7 days for patients with MRSA infection.  In 
addition,  our infection eradication rate was 100%,  with 
no reported recurrence of infection.  Our protocol for 
two-stage revision THA could contribute to a high 
infection eradication rate and a shortened interval 
between the stages.
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